medigraphic.com
ISSN 1527-3172 (Electronic)

2022, Number 2

<< Back Next >>

MEDICC Review 2022; 24 (2)

Community-Acquired Uropathogenic Escherichia coli, Antimicrobial Susceptibility, and Extended-Spectrum Beta-Lactamase Detection

Carmona-Cartaya Y, Hidalgo-Benito M, Borges-Mateus LM, Pereda-Novales N, González-Molina MK, Quiñones D

Language: English
References: 28
Page: 20-25
PDF size: 262.85 Kb.


ABSTRACT

INTRODUCTION Urinary tract infection is the second-leading reason for consults in primary health care. Bacterial urinary tract infections are the most common, of which Escherichia coli is the main etiologic agent. Antimicrobial resistance and multidrug resistance complicate effective community treatment, especially if resistance is caused by extended-spectrum beta-lactamase production. WHO recommends that antimicrobial susceptibility be evaluated in different regions of the world at different times. Community-acquired E. coli’s susceptibility to colistin has not yet been studied in Cuba, and mcr-1 gene screening is necessary.
OBJECTIVE Evaluate community-acquired uropathogenic E. coli isolates’ susceptibility to antibiotics, including colistin, and identify extended-spectrum beta-lactamase–producing bacteria.
METHODS We conducted a descriptive cross-sectional study that included 281 community-acquired uropathogenic E. coli isolates (153 from the Isle of Youth Special Municipality’s Hygiene, Epidemiology, and Microbiology Center and 128 from Microbiology Laboratories of 7 institutions in Havana) from June 2016 through July 2018. We used the disk diffusion method to determine susceptibility to ampicillin, ampicillin/sulbactam, cefazolin, trimethoprim/sulfamethoxazole, ciprofloxacin, nitrofurantoin and fosfomycin. The disk elution method was used to determine susceptibility to colistin. The combined disk method was used to identify extended-spectrum beta-lactamases. Estimates were made regarding the frequency and percentages of antimicrobial susceptibility and resistance, as well as multidrug-resistance patterns.
RESULTS Of the 281 isolates, 68.3% (192/281) were resistant to ampicillin, 54.8% (154/281) were resistant to ciprofloxacin, and 49.5% (139/281) were resistant to trimethoprim/sulfamethoxazole. Resistance to colistin was not detected. On the other hand, 14.2% (40/281) were susceptible to the 8 antibiotics we evaluated, 22.1% (62/281) showed resistance to only 1 antibiotic, and 63.7% (179/281) were resistant to 2 or more antibiotics. In the extended-spectrum beta-lactamase determination, 34.5% (97/281) had inhibition zones ≤14 mm with cefazolin. Of those with inhibition zones, 64.9% (63/97) were positive in the phenotype test, and 35.1% (34/97) were negative. In extended-spectrum beta-lactamase–producing bacteria, 1.6% (1/63) were resistant to fosfomycin, and 3.2% (2/63) were resistant to nitrofurantoin. The most common multidrug-resistance pattern (22.9%; 30/131) was to ampicillin/sulbactam, ampicillin, cefazolin, ciprofloxacin, and trimethoprim/sulfamethoxazole.
CONCLUSIONS Uropathogenic E. coli resistance to the antibiotics most frequently used in community medical practice is quite common, and extended-spectrum beta-lactamase–producing bacteria is the mechanism for beta-lactam antibiotic resistance. Multidrug-resistance patterns include resistance to the antibiotics most used in community-acquired infections. Fosfomycin and nitrofurantoin are the most active in extended-spectrum beta-lactamase producing bacteria. All the isolates were susceptible to colistin.


REFERENCES

  1. Centers for Disease Control and Prevention[Internet]. Atlanta: Center for Disease Controland Prevention; c2022. Prescripción y uso deantibióticos. Infección urinaria; [updated 2021Sep 17; cited 2022 Mar 13]. Available at: https://www.cdc.gov/antibiotic-use/community/sp/for-patients/common-illnesses/uti.html. Spanish.

  2. Gonzáles Rodríguez AO, Barrón Pastor HJ,Gutiérrez Villafuerte CA, Llimpe Mitma de BarrónYL, Huerta Canales de Miranda DV, Suárez S. Clasificación fi logenética de Escherichia coli uropatógenay respuesta inmunometabólica en adultosmayores con infección urinaria en casas de reposo.Arch Med. 2019 Jul 24;19(2):238–46. https://doi.org/10.30554/archmed.19.2.3334.2019.Spanish.

  3. Cabrera Rodríguez LE, Díaz Rigau L,Miralles Suárez AI, Ones Roque R, TorresHerrera Y, Pantaleón Hernández M. Efectividadin vitro de la amikacina y fosfomicinaen cepas de Escherichia coli uropatógenamultidrogorresistentes. CCM [Internet]. 2019Jul 23 [cited 2022 Jan 15];23(4). Availableat: http://www.revcocmed.sld.cu/index.php/cocmed/article/view/3253/1686. Spanish.

  4. Galindo Méndez M. Caracterización moleculary patrón de susceptibilidad antimicrobiana deEscherichia coli productora de β-lactamasas deespectro extendido en infección del tracto urinarioadquirida en la comunidad. Rev Chilena Infectol.2018;35(1):29–35. https://dx.doi.org/10.4067/s0716-10182018000100029. Spanish.

  5. Navarro NM, Euan BOG, Bolado ME, MorenoIGM, Castillón CLG, Robles ZRE. Dos años devigilancia de la resistencia a los antibióticos deEscherichia coli uropatógena en una clínica demedicina familiar. Enf Inf Microbiol. 2017 Apr–Jun;37(2):40–4. Spanish.

  6. Liu YY, Wang Y, Walsh TR, Yi LX, ZhangR, Spencer J, et al. Emergence of plasmidmediatedcolistin resistance mechanism MCR-1 in animals and human beings in China: amicrobiological and molecular biological study.Lancet Infect Dis. 2016 Feb 1;16(2):161–8.http://dx.doi.org/10.1016/S1473-3099(15)00424-7.

  7. Protocolo de Trabajo Red WHONET-Argentina[Internet]. Córdoba: RED WHONET-Argentina;2017 [cited 2018 Oct 15]. 38 p. Available at:http://antimicrobianos.com.ar/ATB/wp-content/uploads/2014/10/Protocolo-WHONET-consensuado-agosto-2014-FINAL-2.pdf. Spanish.

  8. Servicio Antimicrobianos del INEI-ANLIS “Dr.Carlos G. Malbrán”. Alerta epidemiológica:MCR-1 en Argentina. Emergencia de resistenciaplasmídica (transferible) a colistin/polimixina[Internet]. Buenos Aires: Servicio Antimicrobianosdel INEI-ANLIS “Dr. Carlos G. Malbrán”; 2016Feb [cited 2020 Mar 13]. 9 p. Available at:http://antimicrobianos.com.ar/ATB/wp-content/uploads/2016/02/Alerta-epidemiol%C3%B3gico.pdf. Spanish.

  9. Argüez de Paz AR, Rodríguez Chávez A, RojasHernández N. Klebsiella pneumoniae y Escherichiacoli productoras de betalactamasas enpacientes con infección del tracto urinario. RevCub Med Int Emerg. 2015 Sep 8;14(4):16–29.

  10. Quiñones D, Soe Aung M, Carmona Y, PeredaNovales N, Kobayashi N. Molecular epidemiologyand prevalence of extended-spectrum betalactamaseand carbapenemase genes of extraintestinalpathogenic Escherichia coli in Cuba.Proceedings of the 29th ECCMID Congress; 2019Apr 13–16; Amsterdam, Netherlands, 2019.

  11. Velasco J, Araque MC, Araujo E, Longa A,Nieves B, Ramírez AC, et al. Manual práctico debacteriología clínica. Práctica 2: Prueba de susceptibilidadantimicrobiana. 1st digital ed [Internet].Mérida (VE): Universidad de Los Andes;2011. p. 25–9. Available at: https://docplayer.es/16647412-Manual-practico-de-bacteriologia-clinica.html. Spanish.

  12. Servicio Antimicrobianos del INEI-ANLIS “Dr.Carlos G. Malbrán”. Método de elución de discosde colistín. Protocolo adaptado por el LaboratorioNacional de Referencia [Internet]. Buenos Aires:Servicio Antimicrobianos del INEI-ANLIS “Dr.Carlos G. Malbrán”; 2017 Aug [cited 2020 Mar20]. 4 p. Available at: http://antimicrobianos.com.ar/ATB/wp-content/uploads/2017/09/Protocolo-Met-de-Eluci%C3%B3n-de-Discos-de-COL-version2-Agosto2017.pdf. Spanish.

  13. Vieira Franco de Godoy Carvalhaes CH, GalesAC. Manual de Mecanismos de Resistencia aAntibióticos. Fosfomicina. Curso online Iberoamericano:Interpretación del antibiograma en la prácticaclínica diaria [Internet]. Stockholm: EuropeanCommittee on Antimicrobial Susceptibility Testing(EUCAST); 2016 [cited 2020 Mar 13]. 14 p.Available at: https://dokumen.tips/documents/manual-de-mecanismos-de-resistencia-a-antibio-este-complejo-se-une-a-sitios.html. Spanish.

  14. Clinical and Laboratory Standards Institute (CLSI).Performance Standards for Antimicrobial disk susceptibilitytests. M100 29th ed [Internet]. Pennsylvania:Clinical and Laboratory Standars Institute(CSLI); 2019 [cited 2020 Mar 13]. 25 p. Available at:https://clsi.org/media/2663/m100ed29_sample.pdf

  15. González J, Maguiña C, González FM. Laresistencia a los antibióticos: un problema muyserio. Acta Med Peru [Internet]. 2019 Apr–Jun[cited 2020 Mar 15];36(2):145–51. Available at:http://www.scielo.org.pe/scielo.php?pid=S1728-59172019000200011&script=sci_arttext&tlng=en.Spanish.

  16. Guzmán M, Salazar E, Cordero V, Castro A, VillanuevaA, Rodulfo H, et al. Multidrug resistanceand risk factors associated with communityacquiredurinary tract infections caused by Escherichiacoli in Venezuela. Biomédica. 2018 Apr9;39(Suppl 1):96–106. https://doi.org/10.7705/biomedica.v39i2.4030

  17. Garza Montúfar ME, Treviño Valdez PD, Dela Garza Salinas LH. Resistencia bacteriana ycomorbilidades presentes en pacientes urológicosambulatorios con urocultivos positivos. Rev MedInst Mex Seguro Soc [Internet]. 2018 May [cited2020 Mar 15];56(4):347–53. Available at: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=84101. Spanish.

  18. Expósito Boue LM, Bermellón Sánchez S, LescailleGarbey L, Delgado Rondón N, Aliaga CastellanosI. Resistencia antimicrobiana de la Escherichiacoli en pacientes con infección del tracto urinario.Rev Inf Cient [Internet]. 2019 Nov–Dec [cited 2021Dec 16];98(6):755–64. Available at: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1028-99332019000600755&lng=es. Epub 2019 Dec18. Spanish.

  19. Marrero Escalona JL, Leyva Toppes M, CastellanosHeredia JE. Infección del tractourinario y resistencia antimicrobiana en la comunidad.Rev Cubana Med Gen Integr. 2015 Jan–Mar;31(1):78–84. Spanish.

  20. Suárez Trueba B, Milián Samper Y, EspinosaRivera F, Hart Casares M, Llanes Rodríguez N,Martínez Batista ML. Susceptibilidad antimicrobianay mecanismos de resistencia de Escherichiacoli aisladas a partir de urocultivos en un hospitalde tercer nivel. Rev Cubana Med. 2014 Jan–Mar;53(1):3–13. Spanish.

  21. Muiños Torres JC, Alvarez Varela E, CaraviaPubillones I, Peña Brito I. Resistencia a antibióticosen aislamientos de Escherichia coli eninfecciones del tracto urinario inferior adquiridasen la comunidad: diferencias en relación con laedad. Revista CENIC Cienc Biol [Internet]. 2008Sep–Dec [cited 2021 Dec 16];39(3). Availableat: https://revista.cnic.edu.cu/index.php/RevBiol/article/download/686/564/1485. Spanish.

  22. González Colón Y, Duquesne Alderete A, RuizTurcás M. Caracterización epidemiológica ymicrobiológica de las infecciones del tracto urinarioen el Hospital Ortopédico Docente FructuosoRodríguez. Año 2015. Panorama Cuba ySalud [Internet]. 2018 May 18 [cited 2021 Dec16];13(2):11–7. Available at: http://www.revpanorama.sld.cu/index.php/panorama/article/view/11-17. Spanish.

  23. Huttner A, Kowalczyk A, Turjeman A, Babich T,Brossier C, Eliakim-Raz N, et al. Eff ect of 5-dayNitrofurantoin vs single-dose Fosfomycin on clinicalresolution of uncomplicated lower urinary tractinfection in women. A randomized clinical trial.JAMA. 2018 May 1;319(17):1781–9. https://doi.org/10.1001/jama.2018.3627

  24. Hernández MS, García JA, Muñoz JL. Actividadin vitro de fosfomicina frente a enterobacterias deorigen urinario productoras de betalactamasasde espectro extendido. Rev Esp Quimioter [Inter-net]. 2009 Mar [cited 2021 Dec 16];22(1):25–9.Available at: https://pesquisa.bvsalud.org/portal/resource/pt/ibc-77644. Spanish.

  25. Urquizo Ayala G, Arce Chuquimia J, AlanocaMamani G. Resistencia bacteriana por betalactamasasde espectro extendido: un problema creciente.Rev Med La Paz [Internet]. 2018 Jul–Dec[cited 2021 Dec 16];24(2):77–83. Available at:http://www.scielo.org.bo/scielo.php?script=sci_arttext&pid=S1726-89582018000200012. Spanish.

  26. Aguilar Zapata D. E. coli BLEE, la enterobacteriaque ha atravesado barreras. Rev Invest Med SurMex. 2015;22(2):57–63. Spanish.

  27. García-Tello A, Gimbernat H, Redondo C, AranaDM, Cacho J, Angulo JC. Betalactamasas deespectro extendido en las infecciones del tracto urinariocausadas por enterobacterias: aproximacióna su conocimiento y pautas de actuación. ActasUrol Esp. 2014 Dec;38(10):678–84. http://dx.doi.org/10.1016/j.acuro.2014.05.004. Spanish.

  28. Losada I, Barbeito G, García-Garrote F, Fernández-Pérez B, Malvar A, Hervada X, et al. Estudiode sensibilidad de Escherichia coli productoresde infecciones del tracto urinario comunitariasen Galicia. Período: 2016-2017. Atención Primaria.2020 Aug–Sep;52(7):462–8. https://doi.org/10.1016/j.aprim.2019.06.007. Spanish.




2020     |     www.medigraphic.com